Stanford University


Showing 81-90 of 302 Results

  • Mark A. Kay, M.D., Ph.D.

    Mark A. Kay, M.D., Ph.D.

    Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics

    Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.

  • Debra Lee Kaysen

    Debra Lee Kaysen

    Professor of Psychiatry and Behavioral Sciences (Public Mental Health & Population Sciences)

    Current Research and Scholarly InterestsMuch of my current research focus is on the development of testing of accessible, scaleable, and effective treatments for trauma-related disorders and related comorbidities (e.g. substance use disorders, HIV, mood disorders). This work has focused on addressing trauma-related disorders especially in underserved populations and settings. This includes research in rural communities, with Native American communities, and with sexual minorities. My research has had a strong impact on building an evidence base on adaptations of psychotherapies for PTSD and substance use disorders for diverse populations both within and outside the United States. Our findings demonstrate that complex cognitive behavioral psychotherapies like Cognitive Processing Therapy can be culturally adapted and delivered in challenging settings (conflict settings, high poverty environments) with significant and lasting change in PTSD, depression, and functioning. This has led to work adapting CPT for diverse populations within the United States (rural Native Americans, urban Latinos) and outside of it (Iraq, DRC). Other research has focused on treatment for PTSD/SUD. My research has also found support for the use of brief telehealth interventions to build treatment engagement and to reduce drinking among trauma-exposed populations. In addition, my work has been critical in testing the feasibility of novel trauma-focused interventions for use by those with PTSD and SUD, thus paving the road for more rigorous research studies.

    Current PI'ed research studies include: 1) developing and evaluating a brief motivational interviewing intervention designed to increase treatment-seeking among military personnel with untreated PTSD; a two-arm randomized comparative effectiveness trial to evaluate prevention of HIV/STI sexual risk behavior by addressing PTSD through Narrative Exposure Therapy or substance use through Motivational Interviewing among Native American men and women with PTSD; and 3) a comparison of outcomes among patients randomized to initially receive pharmacotherapy or Written Exposure Therapy delivered in primary care as well as comparing outcomes among patients randomized to treatment sequences (i.e., switching and augmenting) for patients who do not respond to the initial treatment.

  • Electron Kebebew, MD, FACS

    Electron Kebebew, MD, FACS

    Harry A. Oberhelman, Jr. and Mark L. Welton Professor

    Current Research and Scholarly InterestsDr. Kebebew’s translational and clinical investigations have three main scientific goals: 1) to develop effective therapies for fatal, rare and neglected endocrine cancers, 2) to identify new methods, strategies and technologies for improving the diagnosis and treatment of endocrine neoplasms and the prognostication of endocrine cancers, and 3) to develop methods for precision treatment of endocrine tumors.

  • Corey Keller, MD, PhD

    Corey Keller, MD, PhD

    Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)

    Current Research and Scholarly InterestsThe goal of my lab is to understand the fundamental principles of human brain plasticity and build trans-diagnostic real-time monitoring platforms for personalized neurotherapeutics.

    We use an array of neuroscience methods to better understand the basic principles of how to create change in brain circuits. We use this knowledge to develop more effective treatment strategies for depression and other psychiatric disorders.

  • Jennifer Keller

    Jennifer Keller

    Clinical Professor, Psychiatry and Behavioral Sciences

    Current Research and Scholarly Interestsinterpersonal violence and abuse prevention; empowerment of women; cognitive and affective information processing in depression; clinical, biological, and neuropsychological aspects of depression; South Asian mental health

  • Kevin Kelley

    Kevin Kelley

    Assistant Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology)

    BioAs a neuroscientist and psychiatrist, I am motivated by how little we understand about the pathophysiology of psychiatric disorders and hope that further knowledge will help to alleviate the ongoing distress of many of our patients. My research program leverages computational genomics, human brain cellular models, and molecular neuroscience techniques to understand the cellular and molecular mechanisms of human brain development and how dysfunction in these processes lead to psychiatric disorders.

  • Joan Kendig

    Joan Kendig

    Professor of Biology in the Department of Anesthesia, Emeritus

    Current Research and Scholarly InterestsMy laboratory tries to find out how pharmacologic agents used in the practice of anesthesia (general anesthetic and analgesic agents) lead to therapeutically desireable endpoints including unconsciousness, immobility and absence of pain. The old idea that general anesthetics are uniformly non-specific "membrane stabilizers" is giving way to a new realization that these agents exert specific actions on particular ion channels and intracellular signalling systems.

  • Vanessa Kennedy

    Vanessa Kennedy

    Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    BioDr. Kennedy is a board-certified hematologist and medical oncologist who specializes in the treatment of myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myelofibrosis (MF). She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine.

    Dr. Kennedy's research focuses on the use of clinical informatics and bioinformatics in understanding cancer biology and improving patient outcomes. She is also actively involved in interventional clinical trials. Her work has been supported by grant funding from the American Society of Clinical Oncology, the American Society of Hematology, and the Chan-Zuckerberg Foundation.